Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study.
adolescents
recombinant human growth hormone
scoliosis
side effects
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
02
03
2023
received:
09
11
2022
accepted:
07
03
2023
medline:
9
5
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
ppublish
Résumé
We aimed to evaluate the risk of developing adolescent scoliosis among recipients of recombinant human growth hormone (rhGH). This registry-based cohort study included 1314 individuals who initiated rhGH treatment since 2013, treated during 10-18 years of age for at least 6 months. This group was matched to a comparison group of 6570 individuals not treated with rhGH. Demographic and clinical information was extracted from the electronic database. The results are presented using hazard ratios (HR) and 95% confidence intervals (CI). During a median follow-up of 4.2 years, 59 (4.5%) rhGH recipients and 141 individuals (2.1%) from the comparison group were diagnosed with adolescent scoliosis. The age at diagnosis did not differ between the groups (14.7 versus 14.3 years, p = 0.095). Patients treated with rhGH were more likely diagnosed with scoliosis (HR 2.12, 95% CI 1.55-2.88, p < 0.001). Among males, the risk was about three times greater in the treated versus the comparison group (HR 3.15, 95% CI 2.12-4.68, p < 0.001), while in females the risk was not increased (HR 1.12, 95% CI 0.72-2.04, p = 0.469). Recombinant human growth hormone treatment was associated with an increased risk to be diagnosed with adolescent scoliosis in males. Scoliosis development should be monitored appropriately in rhGH recipients.
Substances chimiques
Human Growth Hormone
12629-01-5
Recombinant Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240-1248Informations de copyright
© 2023 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.
Références
Konieczny MR, Senyurt H, Krauspe R. Epidemiology of adolescent idiopathic scoliosis. J Child Orthop. 2013;7(1):3-9.
Cheng JC, Castelein RM, Chu WC, et al. Adolescent idiopathic scoliosis. Nat Rev Dis Primers. 2015;1:15030.
Negrini S, Donzelli S, Aulisa AG, et al. 2016 SOSORT guidelines: orthopaedic and rehabilitation treatment of idiopathic scoliosis during growth. Scoliosis Spinal Disord. 2018;13:3.
Latalski M, Danielewicz-Bromberek A, Fatyga M, Latalska M, Kröber M, Zwolak P. Current insights into the aetiology of adolescent idiopathic scoliosis. Arch Orthop Trauma Surg. 2017;137(10):1327-1333.
Kikanloo SR, Tarpada SP, Cho W. Etiology of adolescent idiopathic scoliosis: a literature review. Asian Spine J. 2019;13(3):519-526.
Liang ZT, Guo CF, Li J, Zhang HQ. The role of endocrine hormones in the pathogenesis of adolescent idiopathic scoliosis. FASEB J. 2021;35(9):e21839.
Kulis A, Zarzycki D, Jaskiewicz J. Concentration of estradiol in girls with idiophatic scoliosis. Ortop Traumatol Rehabil. 2006;8(4):455-459.
Wang YJ, Yu HG, Zhou ZH, Guo Q, Wang LJ, Zhang HQ. Leptin receptor metabolism disorder in primary chondrocytes from adolescent idiopathic scoliosis girls. Int J Mol Sci. 2016;17(7):1160.
Yu HG, Zhang HQ, Zhou ZH, et al. High ghrelin level predicts the curve progression of adolescent idiopathic scoliosis girls. Biomed Res Int. 2018;2018:9784083.
Goultidis TT, Papavasiliou KA, Petropoulos AS, Philippopoulos A, Kapetanos GA. Higher levels of melatonin in early stages of adolescent idiopathic scoliosis: toward a new scenario. J Pediatr Orthop. 2014;34(8):768-773.
Ylikoski M. Growth and progression of adolescent idiopathic scoliosis in girls. J Pediatr Orthop B. 2005;14(5):320-324.
Yrjonen T, Ylikoski M. Effect of growth velocity on the progression of adolescent idiopathic scoliosis in boys. J Pediatr Orthop B. 2006;15(5):311-315.
Ahl T, Albertsson-Wikland K, Kalen R. Twenty-four-hour growth hormone profiles in pubertal girls with idiopathic scoliosis. Spine (Phila Pa 1976). 1988;13(2):139-142.
Willner S, Nilsson KO, Kastrup K, et al. Growth hormone and somatomedin a in girls with adolescent idiopathic scoliosis. Acta Paediatr Scand. 1976;65(5):547-552.
Dymling JF, Willner S. Progression of a structural scoliosis during treatment with growth hormone. A case report. Acta Orthop Scand. 1978;49(3):264-268.
Vidil A, Journeau P, Soulie A, Padovani JP, Pouliquen JC. Evolution of scoliosis in six children treated with growth hormone. J Pediatr Orthop B. 2001;10(3):197-200.
Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361-397.
Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167-177.
Coutant R, Bosch Munoz J, Dumitrescu CP, et al. Effectiveness and overall safety of NutropinAq® for growth hormone deficiency and other Paediatric growth hormone disorders: completion of the international cooperative growth study, NutropinAq® European registry (iNCGS). Front Endocrinol (Lausanne). 2021;12:676083.
Savendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER. J Clin Endocrinol Metab. 2021;106(6):1728-1741.
Wang ED, Drummond DS, Dormans JP, Moshang T, Davidson RS, Gruccio D. Scoliosis in patients treated with growth hormone. J Pediatr Orthop. 1997;17(6):708-711.
Day GA, McPhee IB, Batch J, et al. Growth rates and the prevalence and progression of scoliosis in short-statured children on Australian growth hormone treatment programmes. Scoliosis. 2007;2:3.
Yun YH, Kwon SS, Koh Y, Kim DJ, Ahn J, Lee SY. Influence of growth hormone treatment on radiographic indices of the spine: propensity-matched analysis. J Orthop Surg Res. 2017;12(1):130.
Park SJ, Lee KH, Lee CS, et al. Impact of growth hormone treatment on scoliosis development and progression: analysis of 1128 patients with idiopathic short stature. J Pediatr Endocrinol Metab. 2020;34(2):243-250.
Ben-Ari T, Chodick G, Shalev V, Goldstein D, Gomez R, Landau Z. Real-world treatment patterns and outcomes of growth hormone treatment among children in Israel over the past decade (2004-2015). Front Pediatr. 2021;9:711979.
Libruder C, Blumenfeld O, Dichtiar R, et al. Mortality and cancer incidence among patients treated with recombinant growth hormone during childhood in Israel. Clin Endocrinol (Oxf). 2016;85(5):813-818.
Grimberg A, Huerta-Saenz L, Grundmeier R, et al. Gender bias in U.S. pediatric growth hormone treatment. Sci Rep. 2015;5:11099.
Dimeglio A, Canavese F. Progression or not progression? How to deal with adolescent idiopathic scoliosis during puberty. J Child Orthop. 2013;7(1):43-49.
Dimeglio A, Canavese F. The immature spine: growth and idiopathic scoliosis. Ann Transl Med. 2020;8(2):22.
Goldberg CJ, Dowling FE, Fogarty EE. Adolescent idiopathic scoliosis: is rising growth rate the triggering factor in progression? Eur Spine J. 1993;2(1):29-36.